These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23027188)

  • 1. Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.
    Hull CM; Bader O; Parker JE; Weig M; Gross U; Warrilow AG; Kelly DE; Kelly SL
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6417-21. PubMed ID: 23027188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals.
    Eddouzi J; Parker JE; Vale-Silva LA; Coste A; Ischer F; Kelly S; Manai M; Sanglard D
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3182-93. PubMed ID: 23629718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B.
    Hull CM; Parker JE; Bader O; Weig M; Gross U; Warrilow AG; Kelly DE; Kelly SL
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4223-32. PubMed ID: 22615281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
    Sanglard D; Coste AT
    Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
    Swinne D; Watelle M; Nolard N
    Rev Iberoam Micol; 2005 Mar; 22(1):24-8. PubMed ID: 15813679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
    Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STB5 is a negative regulator of azole resistance in Candida glabrata.
    Noble JA; Tsai HF; Suffis SD; Su Q; Myers TG; Bennett JE
    Antimicrob Agents Chemother; 2013 Feb; 57(2):959-67. PubMed ID: 23229483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous Expression of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery.
    Keniya MV; Ruma YN; Tyndall JDA; Monk BC
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
    Chen TC; Chen YH; Chen YC; Lu PL
    Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.
    Posteraro B; Martucci R; La Sorda M; Fiori B; Sanglard D; De Carolis E; Florio AR; Fadda G; Sanguinetti M
    J Clin Microbiol; 2009 Jun; 47(6):1927-30. PubMed ID: 19403774
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Ahmad S; Joseph L; Parker JE; Asadzadeh M; Kelly SL; Meis JF; Khan Z
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30455247
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
    Martel CM; Parker JE; Bader O; Weig M; Gross U; Warrilow AG; Rolley N; Kelly DE; Kelly SL
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4527-33. PubMed ID: 20733039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata.
    Nagappan V; Boikov D; Vazquez JA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):522-5. PubMed ID: 19841143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of azole resistance among clinical isolates of Candida glabrata in Poland.
    Szweda P; Gucwa K; Romanowska E; Dzierz Anowska-Fangrat K; Naumiuk Ł; Brillowska-Da Browska A; Wojciechowska-Koszko I; Milewski S
    J Med Microbiol; 2015 Jun; 64(6):610-619. PubMed ID: 25818698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UPC2A is required for high-level azole antifungal resistance in Candida glabrata.
    Whaley SG; Caudle KE; Vermitsky JP; Chadwick SG; Toner G; Barker KS; Gygax SE; Rogers PD
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4543-54. PubMed ID: 24867980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.
    Drago M; Scaltrito MM; Morace G;
    Eur J Clin Microbiol Infect Dis; 2004 Aug; 23(8):619-24. PubMed ID: 15258831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole-induced inhibition of the fungicidal activity of amphotericin B in Candida strains with reduced susceptibility to voriconazole: an effect not predicted by the MIC value alone.
    Lignell A; Löwdin E; Cars O; Sanglard D; Sjölin J
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1629-37. PubMed ID: 21282443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole.
    Borst A; Raimer MT; Warnock DW; Morrison CJ; Arthington-Skaggs BA
    Antimicrob Agents Chemother; 2005 Feb; 49(2):783-7. PubMed ID: 15673768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and Antifungal Susceptibility of the Emerging Fungal Species,
    Sikora M; Kuthan R; Piskorska-Malolepsza K; Golas-Pradzynska M; Domański D; Augustynowicz-Kopeć E; Swoboda-Kopec E
    Pol J Microbiol; 2019 Sep; 68(3):303-308. PubMed ID: 31880875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Transcriptomics Approach To Unveiling the Mechanisms of
    Cavalheiro M; Costa C; Silva-Dias A; Miranda IM; Wang C; Pais P; Pinto SN; Mil-Homens D; Sato-Okamoto M; Takahashi-Nakaguchi A; Silva RM; Mira NP; Fialho AM; Chibana H; Rodrigues AG; Butler G; Teixeira MC
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.